How to Get Rezdiffra (Resmetirom) in Michigan

Who Is Eligible for Rezdiffra?

The December 2025 prescribing information indicates Rezdiffra, with diet and exercise, for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis consistent with stages F2-F3. Approval is accelerated based on improvement in MASH and fibrosis; continued approval may depend on confirmation of clinical benefit.

An elevated ALT, fatty liver on ultrasound, or one FibroScan value does not by itself establish that labeled diagnosis. The clinician should integrate metabolic risk, liver tests, fibrosis assessment, imaging, competing causes of liver disease, and evidence of cirrhosis or decompensation.

Step 1: Find the Right Michigan Evaluation

Primary-care clinicians can identify MASLD risk and order initial testing, but Rezdiffra access often involves gastroenterology or hepatology because fibrosis staging, differential diagnosis, and payer documentation are specialized. A clinician must be authorized to treat a patient located in Michigan.

Telehealth may cover history, result review, and follow-up, but it cannot guarantee that all diagnostic work can be done remotely. Imaging, elastography, blood tests, or an examination may still be needed. Rezdiffra is not a controlled substance, so access does not hinge on controlled-drug telemedicine rules.

Step 2: Document MASH and Fibrosis Risk

AASLD's resmetirom update describes a noninvasive-test pathway for identifying appropriate patients and does not require liver biopsy in every case. Depending on the situation, documentation may include FIB-4, VCTE/FibroScan, magnetic resonance elastography, ELF, MRI-based fat assessment, or biopsy.

Payers can adopt their own criteria, which may be narrower or require particular thresholds. A complete prior-authorization packet commonly needs:

• diagnosis and absence of decompensated cirrhosis;
• evidence supporting F2-F3 fibrosis;
• relevant liver tests and imaging;
• weight for labeled dosing;
• current medicines and interaction review;
• prescriber specialty or consultation when the plan requires it.

No single checklist guarantees approval, and a missing item should be clarified with the plan rather than replaced by invented test results.

Step 3: Review the Current Label

The current weight-based dose is 80 mg once daily for patients under 100 kg and 100 mg once daily for patients at or above 100 kg. It can be taken with or without food and should be swallowed whole rather than split, crushed, or chewed.

Important safety and interaction areas include:

• Hepatotoxicity: the label directs monitoring for elevations in liver tests and liver-related adverse reactions.
• Gallbladder events: gallstones, cholecystitis, and gallstone pancreatitis occurred more often than with placebo; suspected acute events can require interruption.
• Statins: Rezdiffra increases exposure to atorvastatin, pravastatin, rosuvastatin, and simvastatin, so label-specific statin limits and adverse-effect monitoring matter.
• CYP2C8 and transporters: strong CYP2C8 inhibitors such as gemfibrozil should be avoided; clopidogrel requires a Rezdiffra dose reduction. OATP1B1/1B3 inhibitors can also be relevant.

The label does not provide the same fixed “baseline, week 4, week 12” laboratory schedule for every patient. The prescriber should set follow-up from liver status, symptoms, interacting medicines, and payer requirements.

Step 4: Complete Prior Authorization and Pharmacy Routing

Ask the plan four questions before the prescription is sent:

1. Is Rezdiffra on the current formulary?
2. Which fibrosis tests and thresholds are accepted?
3. Is a hepatologist or gastroenterologist required?
4. Which specialty pharmacy must dispense it?

Commercial plans, Medicare Part D plans, and Michigan Medicaid managed-care plans can use different forms. “Michigan Medicaid covers Rezdiffra” is therefore too broad; the member's exact plan and current criteria must be checked.

If denied, obtain the written reason. Missing documentation can often be resubmitted. A clinical-criteria denial may require an appeal that explains the diagnosis and evidence. Manufacturer support may help eligible patients navigate benefits or affordability, but program eligibility, dollar limits, and government-insurance exclusions can change.

Step 5: Start and Follow the Treatment Goal

MAESTRO-NASH showed that both resmetirom doses improved biopsy endpoints at 52 weeks compared with placebo. The trial did not establish that every patient will feel different or that one FibroScan result will fall by a guaranteed amount.

Follow-up should evaluate adherence, liver tests and symptoms, gallbladder symptoms, thyroid status when clinically relevant, lipid response, statin tolerability, and the overall cardiometabolic plan. Diet, physical activity, diabetes care, lipid management, and alcohol counseling remain part of treatment rather than prerequisites to abandon once the prescription is approved.